Table 5.
Neuro-physical changes.
| HBOT | Control | P-value baseline | Net effect size* | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Change | Three months P-value | Pre | Post | Change | Three months P-value | |||
| N | 14 | 10 | ||||||||
| FIRM | 4.7 ± 3.0 | 3.4 ± 2.9 | −1.3 ± 2.3 | 0.0537 | 4.2 ± 3.0 | 5.1 ± 2.9 | 0.9 ± 2.1 | 0.2042 | 0.6959 | −0.997 |
| FOAM | 5.6 ± 3.2 | 6.1 ± 4.2 | 0.5 ± 5.8 | 0.7533 | 7.4 ± 5.0 | 7.3 ± 5.5 | −0.1 ± 2.6 | 0.9074 | 0.3278 | 0.125 |
| BESS (< 12) | 10.4 ± 4.6 | 9.6 ± 7.0 | −0.8 ± 6.8 | 0.6714 | 11.9 ± 8.2 | 11.6 ± 8.1 | −0.3 ± 4.3 | 0.8321 | 0.5796 | -0.082 |
Baseline comparison of p-values test the null hypothesis of equal means of the two groups at baseline using an unpaired t-test; three-month comparison of p-values test the null hypothesis of equal means of each group pre-post intervention (HBOT/sham respectively) using a paired t-test; bold, P < 0.05, net effect size is the subtraction of Cohen’s D effect size of the control group from the HBOT group Cohen’s D effect size.